|
Volumn 60, Issue 2, 2005, Pages 127-136
|
Drug Regulation 2056
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
THALIDOMIDE;
BIOINFORMATICS;
BIOLOGICAL WARFARE;
CONSUMER;
COST EFFECTIVENESS ANALYSIS;
DECISION MAKING;
DRUG EFFICACY;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
FUTUROLOGY;
GOVERNMENT;
HEALTH CARE DELIVERY;
HEALTH STATUS;
HUMAN;
HUMAN GENOME;
NUTRITION;
POSTMARKETING SURVEILLANCE;
QUALITY CONTROL;
REVIEW;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
TERRORISM;
VIRTUAL REALITY;
BIOTERRORISM;
CLINICAL TRIALS;
DELIVERY OF HEALTH CARE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG THERAPY, COMBINATION;
FORECASTING;
GENOME, HUMAN;
HUMANS;
INTERNATIONAL CLASSIFICATION OF DISEASES;
INTERNATIONAL COOPERATION;
INTERNET;
LEGISLATION, DRUG;
PRODUCT SURVEILLANCE, POSTMARKETING;
QUALITY ASSURANCE, HEALTH CARE;
UNITED STATES;
|
EID: 23444446683
PISSN: 1064590X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (5)
|
References (5)
|